Allogene Therapeutics, Inc.

Analysis for Ticker: ALLO

Allogene Therapeutics Inc develops cancer therapies using cells from healthy donors, but the firm is a machine that runs on a subtraction problem. Imagine a baker who has never sold a single loaf of bread but has already lost 2,0$ billion of other people's money trying to find a recipe. This company survives by baking more and more slices out of the same pie and selling them to neighbors, which makes every existing slice smaller. The current math is a disaster because the insiders are eating the crumbs while the kitchen is still on fire, extracting millions in cash while the business has no actual sales to sustain itself. The mechanism of survival began with a massive injection of public cash in 05/2024, when the company printed 37,9 million new shares to take 105,2$ million from regular investors. Even after firing 28% of its workforce in 05/2025 to slow the bleed, the internal machinery kept siphoning money. The Executive Chair, Arie Belldegrun, used his own entity called Bellco Capital to pull out 40.217$ every single month in consulting fees plus 0,8$ million in bonuses for the year. While the company lost 152,1$ million in the first nine months of 2025, it also paid Belldegrun 0,4$ million in rent for his own office space.